CRISPR Therapeutics
first CRISPR medicine in history, FDA approved Dec 2023 for SCD and Jan 2024 for TDT; ~1,000 US patients ≥12 yr eligible; paediatric sNDA under review 2026.
- Country
- Switzerland
- Ticker
- CRSP
FDA approved
EMA approved
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Genome editing | genome-engineering | Medium | → |
| Personalized & regenerative medicine | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.